Winton Group
JNCE

Winton Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Winton Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,585
Closed -$81K – 1468
2020
Q4 		$81K Sell
11,585
-7,058
-38% -$54.9K 0.01% 1271
2020
Q3 		$152K Buy
+18,643
New +$116K ﹤0.01% 1371

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Winton Group's JNCE Position: Q1 2021 in Review

Winton Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 11,585 shares — an estimated $81K sold.

Winton Group first reported a position in JNCE in Q3 2020 and held it in 2 quarters. The position peaked at $152K in Q3 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

  • Winton Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Winton Group sold 11,585 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $81K.
  • Winton Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Winton Group's Jounce Therapeutics, Inc. Common Stock position peaked at $152K in Q3 2020.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.